November 09, 2022

In Celebration of 20 Years of Paragon CRT® Ortho-K Lenses
ECPs Look Ahead to the Next Two Decades

SAN RAMON, Calif., November 9, 2022CooperVision Specialty EyeCare recently invited eye care professionals (ECPs) from across the world to share their thoughts, hopes, and predictions surrounding the future of myopia management. The survey was conducted in celebration and recognition of the 20th anniversary of the FDA’s approval of Paragon CRT®, the world’s first Ortho-K lens of its kind approved for safe overnight wear.1 The results reveal that ECPs anticipate an increase in the number of patient-facing discussions, prescriptions, and treatment options for myopia management over the next 10 to 20 years.2

The research shows that 80% of practices plan to have more conversations with their patients about myopia and its treatment options, with an average per-respondent goal to fit at least 500 patients in some form of myopia treatment over the next 10 years. In addition, ECPs agreed that the most valuable thing to accelerate myopia management adoption is more educational tools and resources.

One anonymous survey respondent called for “well-crafted literature and other educational materials to provide to parents, pediatricians and family practitioners,” identifying that “one of the biggest hurdles is the amount of time required to discuss myopia management with parents at the time of their child’s eye appointment.”

“The most significant positive change will be that optometrists, ophthalmologists, and pediatricians will routinely discuss ways to slow down myopia in children with parents,” another respondent predicted of the coming decades.

“In the 20 years since the first iteration of Paragon CRT® was introduced, we’ve seen vast change in how the industry views and uses orthokeratology in clinical practice. Ortho-k isn’t new, but for many, the concept of myopia management still is,” said Leah Johnson, OD, FAAO, Director of Professional Affairs, CooperVision Specialty EyeCare. “We’re excited to similarly help shape the next 20 years, partnering with ECPs to provide the tools, resources, and knowledge they need for success.”

In 2002, Paragon lens designs and material (HDS® 100) were the first to receive U.S. Food and Drug Administration approval for overnight wear with no age restrictions, encompassing up to
-6.00D of myopia correction (with or without astigmatism) and 1.75D of astigmatic correction. Both Paragon CRT® and Paragon CRT® Dual Axis contact lenses received CE marking for slowing the progression of myopia in October 2020. Continued innovation has brought growing customization choices as well—most recently in 2021 when CooperVision Specialty Eyecare introduced the 5mm back optic zone diameter (BOZD) for Paragon CRT® and Paragon CRT Dual Axis®, furthering expanding myopia management possibilities for eye care professionals. Paragon lenses for myopia management have been prescribed to over 3 million patients worldwide3 which has helped establish Paragon CRT® as the most recognized Ortho-K brand in the world.4


As a world leader in myopia management, CooperVision’s portfolio also includes iSee®, Dreamlite® and No7 ortho-k lenses, as well as MiSight® 1 day soft dual-focus contact lenses for age-appropriate* children. The company is also part of a joint venture to commercialize spectacle lenses with SightGlass Vision’s Diffusion Optics Technology™ to further grow available myopia interventions. To further support myopia management adoption, the company provides a range of practice building resources, fitting tools and educational events.


# # #



*U.S. MiSight® 1 day Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Sight Glass Vision’s Diffusion Optics Technology is currently not approved in the U.S.


About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit

Media Contact
Maggie Munley, Counselor, McDougall Communications or +1-585-434-2149


1 FDA letter on file.

2 CooperVision data on file, 2022. Survey: Predicting the Future of Myopia Management. N=37 ECPs (U.S., Australia, Canada, Israel, Norway, Switzerland, Thailand, U.K.)

3 CooperVision Specialty EyeCare data on file.

4 CooperVision Specialty EyeCare data on file.